Top

Gepubliceerd in:

01-02-2002 | Artikelen

Immunologische afwijkingen bij het syndroom van Down

Auteur: T. W. Kuijpers

Gepubliceerd in: Tijdschrift voor Kindergeneeskunde | Uitgave 6/2002

samenvatting

In dit artikel wordt ingegaan op de relatie tussen het teveel aan genetisch materiaal op chromosoom 21 en de hematologische en immunologische afwijkingen. De serumimmunoglobulinespiegels zijn op jonge leeftijd over het algemeen normaal. De humorale antistofrespons lijkt echter gestoord. De T-celafhankelijke immuniteit valt binnen de norm. Klinisch lijken er aanwijzingen voor granulocytendysfunctie. De kans op het ontwikkelen van maligniteit of een auto-immuunproces is verhoogd.

vorige artikel Afweerstoornissen als onderdeel van een syndroom

volgende artikel Afwijkingen in fagocyten

Hattori M, Fujiyama A, Taylor TD, et al. The DNA sequence of human chromosome 21. The chromosome 21 mapping and sequencing consortium. Nature 2000;405:311-9.CrossRefPubMed

Isacson O, Seo H, Lin L, et al. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci 2002;25:79-84.CrossRefPubMed

Poirier J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann N Y Acad Sci 2000;924:81-90.PubMed

Solans A, Estivill X, De La Luna S. A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein beta-secreatase. Cytogenet Cell Genet 2000; 89:177-84.CrossRefPubMed

Hallam DM, Capps NL, Travelstead AL, et al. Evidence for an interferon-related inflammatory reaction in the trisomy 16 mouse brain leading to caspase-1-mediated neuronal apoptosis. J Neuroimmunol 2000;110:66-75.CrossRefPubMed

Maroun LE, Heffernan TN, Hallam DM. Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. J Interferon Cytokine Res. 2000;20:197-203.CrossRefPubMed

Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165-9.CrossRefPubMed

Satge D, Sasco AJ, Carlsen NL, et al. A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res 1998;58:448-52.PubMed

Preudhomme C, Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the runt domain of the AML1/PEBP2alphaB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 2000;96:2862-9.PubMed

Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000;96:1094-9.PubMed

Yamada S, Hongo T, Okada S, et al. Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome. Int J Hematol 2001;74:428-36.CrossRefPubMed

Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002;99:245-51.CrossRefPubMed

Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia 2000;14:786-91.CrossRefPubMed

Karandikar NJ, Aquino DB, McKenna RW, Kroft SH. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis. Am J Clin Pathol 2001;116:204-10.CrossRefPubMed

Loh RK, Harth SC, Thong YH, Ferrante A. Immunoglobulin G subclass deficiency and predisposition to infection in Down's syndrome. Pediatr Infect Dis J 1990;9:547-51.PubMed

Van Damme P, Vranckx R, Meheus A. Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome. Vaccine 1990;8:S53-5.CrossRefPubMed

Vajro P, Lettera P, Fontanella A, et al. Vaccination against hepatitis B in preschool children with Down's syndrome. J Intellect Disabil Res 1992;36:77-81.PubMedCrossRef

Philip R, Berger AC, McManus NH, et al. Abnormalities of the in vitro cellular and humoral responses to tetanus and influenza antigens with concomitant numerical alterations in lymphocyte subsets in Down syndrome (trisomy 21). J Immunol 1986;136:1661-7.PubMed

Fekete G, Kulcsar G, Dan P, et al.. Immunological and virological investigations in Down's syndrome. Eur J Pediatr 1982; 138:59-62.CrossRefPubMed

Tazi-Ahnini R, Di Giovine FS, McDonagh AJ, et al. Structure and polymorphism of the uman gene for the interferon-induced p78 protein (MX1): evidence of association with alopecia in the Down syndrome region. Hum Genet 2000;106;639-45.CrossRefPubMed

Karlsson B, Gustafsson J, Hedov G, et al. Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. Arch Dis Child 1998;79:242-5.CrossRefPubMed

Van Goor JC, Massa GG, Hirasing R.Increased incidence and prevalence of diabetes mellitus in Down's syndrome. Arch Dis Child 1997;77:186.PubMed

Anwar AJ, Walker JD, Frier BM. Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications. Diabet Med 1998;15:160-3.CrossRefPubMed

Hansson T, Anneren G, Sjoberg O, et al. Celiac disease in relation to immunologic serum markers, trace elements, and HLA-DR and DQ antigens in Swedish children with Down syndrome. J Pediatr Gastroenterol Nutr 1999;29:286-92.CrossRefPubMed

Csizmadia CG, Mearin ML, Oren A, et al. Accuracy and cost-effectiveness of a new strategy to screen for celiac disease in children with Down syndrome. J Pediatr. 2000;137:743-4.CrossRef

Arentz-Hansen H, Korner R, Molberg O, et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000;191:603-12.CrossRefPubMed

Niveloni S, Pedreira S, Sugai E, et al. The natural history of gluten sensitivity: report of two new celiac disease patients resulting from a long-term follow-up of nonatrophic, first-degree relatives. Am J Gastroenterol 2000;95:463-8.CrossRefPubMed

Bevan S, Popat S, Braegger CP, et al. Contribution of the MHC region to the familial risk of coeliac disease. J Med Genet 1999;36:687-90.PubMed

Shield JP, Wadsworth EJ, Hassold TJ, et al. Is disomic homozygosity at the APECED locus the cause of increased autoimmunity in Down's syndrome? Arch Dis Child 1999;81:147-50.CrossRefPubMed

Peled-Kamar M, Lotem J, Okon E, et al. Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn-superoxide dismutase: implications for Down syndrome. EMBO J 1995; 14:4985-93.PubMed

Paz-Miguel JE, Flores R, Sanchez-Velasco P, et al. Reactive oxygen intermediates during programmed cell death induced in the thymus of the Ts(1716)65Dn mouse, a murine model for human Down's syndrome. J Immunol 1999;163:5399-410.PubMed

Murphy M, Friend DS, Pike-Nobile L, Epstein LB. Tumor necrosis factor-alpha and IFN-gamma expression in human thymus. Localization and overexpression in Down syndrome (trisomy 21). J Immunol 1992;149:2506-12.PubMed

Titel: Immunologische afwijkingen bij het syndroom van Down
Auteur: T. W. Kuijpers
Publicatiedatum: 01-02-2002
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Tijdschrift voor Kindergeneeskunde / Uitgave 6/2002
Print ISSN: 0376-7442
Elektronisch ISSN: 1875-6840
DOI: https://doi.org/10.1007/BF03061366

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 6/2002

Thuisbehandeling met intraveneus immunoglobuline bij patiënten met primaire hypogammaglobulinemie

Immunologie

Kinderen met recidiverende infecties

Afweerstoornissen als onderdeel van een syndroom

Thuisbehandeling met intraveneus immunoglobuline bij patiënten met primaire hypogammaglobulinemie

Regulators of hepatic glucose and glycogen metabolism